The next generation of antidepressants and antipsychotics

24 February 2023
antidepressants-big

An Expert View from David Bleakman, president, Drug Discovery and Development at PsychoGenics.

For decades, the development of the next generations of drugs for neuropsychiatric symptoms has been one of the greatest challenges in neuroscience drug discovery.

In particular, the need to improve upon standard of care with respect to side effects or efficacy in treatment-resistant patient populations. We have seen a lot of novel molecular targets implicated and drugs clinically tested targeting depression, schizophrenia and neurodegenerative disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical